AstraZeneca PLC (AZN)vsenVVeno Medical Corp (NVNO)
AZN
AstraZeneca PLC
$171.61
-3.85%
HEALTHCARE · Cap: $302.65B
NVNO
enVVeno Medical Corp
$11.31
+2.82%
HEALTHCARE · Cap: $7.42M
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
NVNO
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+2.2%
Fair Value
$194.36
Current Price
$171.61
$22.75 discount
Intrinsic value data unavailable for NVNO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : NVNO
The strongest argument for NVNO centers on Price/Book, Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : NVNO
The primary concerns for NVNO are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while NVNO is a value play — different risk/reward profiles.
NVNO carries more volatility with a beta of 1.09 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 27/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
enVVeno Medical Corp
HEALTHCARE · MEDICAL DEVICES · USA
enVVeno Medical Corp (NVNO) is a pioneering medical device firm focused on revolutionizing vascular access solutions for dialysis patients with its proprietary biocompatible technology. By aiming to fulfill essential unmet needs within the dialysis sector, the company enhances the safety and effectiveness of vascular procedures, positioning itself to capture significant growth in the vascular interventions market. With a strong commitment to advanced engineering and compliance with regulatory standards, enVVeno is well-aligned with the dynamic landscape of healthcare, underscoring its mission to elevate patient outcomes in this critical area.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?